Terminated × INDUSTRY × Myelodysplastic Syndromes × Clear all Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
Phase 1 Terminated
106 enrolled 28 charts
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
Phase 1 Terminated
28 enrolled 19 charts
STIMULUS-MDS2
Phase 3 Terminated
530 enrolled 29 charts
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Phase 1/2 Terminated
101 enrolled
A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies
Phase 1 Terminated
25 enrolled
LIMBER
Phase 1/2 Terminated
22 enrolled 28 charts
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Phase 1/2 Terminated
137 enrolled 31 charts
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
Phase 1/2 Terminated
13 enrolled
ACHIEVE
Phase 2 Terminated
16 enrolled
A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Phase 1 Terminated
56 enrolled 24 charts
Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes
Phase 1 Terminated
56 enrolled
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS
Phase 1/2 Terminated
67 enrolled
AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia
Phase 1 Terminated
7 enrolled 16 charts
Connect® Myeloid Disease Registry
Terminated
2,013 enrolled
A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
Phase 1 Terminated
101 enrolled 54 charts
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies
Phase 2 Terminated
7 enrolled 12 charts
A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS
Phase 1 Terminated
7 enrolled
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
Phase 1/2 Terminated
48 enrolled
A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Phase 1 Terminated
68 enrolled
A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies
Phase 1 Terminated
95 enrolled 47 charts
LAUREL
Phase 1 Terminated
2 enrolled
A Study of ONO-7475 in Patients With Acute Leukemias
Phase 1/2 Terminated
42 enrolled 47 charts
IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome
Phase 1/2 Terminated
2 enrolled 14 charts
An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia
Phase 1 Terminated
37 enrolled 14 charts
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Phase 1 Terminated
249 enrolled 43 charts
Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Phase 1 Terminated
39 enrolled
Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome
Phase 1 Terminated
40 enrolled
Encore-MDS
Phase 1 Terminated
127 enrolled
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
Phase 1 Terminated
21 enrolled
A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS
Phase 1/2 Terminated
20 enrolled 13 charts
Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma
Phase 1/2 Terminated
4 enrolled 9 charts
THRIVE
Phase 2/3 Terminated
1 enrolled 9 charts
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
Phase 1/2 Terminated
187 enrolled 8 charts
Thrombosomes® in Bleeding Thrombocytopenic Patients Study
Phase 2 Terminated
21 enrolled
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
Phase 1 Terminated
24 enrolled 21 charts
CATHY
Phase 3 Terminated
11 enrolled 10 charts
Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
Phase 1/2 Terminated
30 enrolled 29 charts
Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.
Phase 1/2 Terminated
1 enrolled
GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
Phase 1/2 Terminated
12 enrolled 20 charts
HATCY
Phase 3 Terminated
63 enrolled 14 charts
A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies
Phase 1 Terminated
40 enrolled
Study of INCB053914 in Subjects With Advanced Malignancies
Phase 1/2 Terminated
97 enrolled 40 charts
Phase I Study of Milatuzumab for Graft Versus Host Disease
Phase 1 Terminated
12 enrolled
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor
Phase 2/3 Terminated
40 enrolled 10 charts
Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
Phase 2 Terminated
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
Phase 1/2 Terminated
69 enrolled 34 charts
Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine
Phase 1/2 Terminated
25 enrolled
A Study of PLX51107 in Advanced Malignancies
Phase 1 Terminated
50 enrolled
A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)
Phase 1 Terminated
28 enrolled
AML/MDS
Phase 1/2 Terminated
13 enrolled